PL 34231

Drug Profile

PL 34231

Alternative Names: LA-12; PLD-147

Latest Information Update: 16 Aug 2007

Price : $50

At a glance

  • Originator PLIVA d.d.
  • Class
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 11 Nov 2004 Phase Ib trial in Solid tumours in Czech Republic (PO)
  • 16 Mar 2004 Phase-I clinical trials in Solid tumours in Czech Republic (PO)
  • 05 Feb 2003 Preclinical trials in Solid tumours in Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top